News and Announcements
Consistent returns for APG mortgage fund
- Published July 22, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Funds manager, Active Property Group, has announced an annualised return of 9.85% (2.46% for the June quarter) for its pooled mortgage fund, a slight improvement on the previous quarter’s result of 9.42% p.a.
The appetite for short-term business loans has remained steady throughout the Covid-19 period. Due to these uncertain times, Mortgage Manager, Private Mortgages Australia (PMA), has introduced more conservative lending policies in order to keep the risk profile to a minimum. PMA has reduced the loan-to-value ratio they will lend at to 70% and is focussing on only lending to borrowers who have strong exit strategies.
The pooled mortgage fund allows investors to invest across a diversified portfolio of commercial loans selected and by an experienced mortgage manager. All investments are secured by Australian real estate with a first or second mortgage. Extensive due diligence is conducted to determine the quality of the investment and conservative loan-to-value ratios are used.
Active Property Group is a funds manager helping our clients to access quality investment opportunities. We work with everyday Australians (both wholesale and retail investors) who are looking to make their money work harder and achieve financial freedom. Our two key areas of investment are mortgages and commercial property. We have experienced and professional investment managers (with skin in the game) who always conduct comprehensive risk management & due diligence assessments.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
